Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled study of MEDI6012 in acute ST-segment elevation myocardial infarction
MOH_2018-04-24_002330Phase 2Not yet recruiting
- Sponsor
- MedImmune
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of recombinant human lecithin-cholesterol acyltransferase in myocardial infarction (MI) (4 arms), sponsored by MedImmune. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2018-04-24_002330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-24_002330.